Description
Remogliflozin Etabonate is used to treat type 2 diabetes mellitus and non-alcoholic steatohepatitis (non-alcoholic fatty liver disease). Diabetes mellitus is a metabolic disease that causes high blood sugar levels. It occurs when the insulin (a hormone produced by the beta cells of the pancreas) is resistant in breaking the glucose to produce energy (insulin resistance), or the pancreas (an organ behind the stomach) produces little or no insulin at all. Remogliflozin Etabonate is not indicated for use in type 1 diabetes.
Remogliflozin Etabonate contains Remogliflozin Etabonate. It belongs to the class of gliflozins. It is a sodium-glucose transporter 2 inhibitor and works by reducing blood sugar levels by eliminating excess sugars from the body through urine. Thus, it helps improve glycaemic control (control of glucose levels) in patients. Remogliflozin Etabonate also lowers the risk of heart failure in type 2 diabetic patients with heart diseases.
Take Remogliflozin Etabonate as advised by your doctor. Some common side effects of Remogliflozin Etabonate include nausea, frequent urge to urinate, low blood sugar levels, fungal infection in the genital area, and increased thirst. These side effects are not familiar to everyone and vary individually. If you notice any side effects that are not manageable, please consult your doctor.
